首页 > 最新文献

Hipertension y Riesgo Vascular最新文献

英文 中文
Prescripción de antihipertensivos en personas con diabetes tipo 2 en Andalucía y recomendaciones SEH-LELHA 2022: evaluación del coste y uso [安达卢西亚 2 型糖尿病患者的抗高血压处方与 SEH-LELHA 2022 准则:经济成本评估]。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.hipert.2024.06.004
D. Martín-Enguix , J.C. Aguirre Rodríguez , M. Guisasola Cárdenas , M.N. Generoso Torres , A. Hidalgo Rodríguez , M. Sánchez Cambronero , A. González Bravo

Objective

This study aims to analyze the prescription of antihypertensive drugs in patients with type 2 diabetes (T2D) in Andalusia, comparing it with the SEH-LELHA 2022 guidelines, and to assess the direct cost of these treatments.

Materials and methods

A multicentric, cross-sectional, and descriptive study was conducted with 385 T2D patients. Participants were randomly selected from the patient lists of 120 primary care physicians from Andalusia. Inclusion criteria included a diagnosis of T2D and complete clinical records for the year 2022. Demographic data and drug prescription information were collected, with the average cost per patient being calculated.

Results

The mean age of the subjects was 70.72 years, with 53.51% being male. A total of 70.9% of the patients were taking antihypertensive drugs, the most common being ACE inhibitors/ARBs (70.9%), diuretics (70.1%), beta-blockers (40.0%), and calcium channel blockers (20.0%). Each patient took an average of 2.46 ± 1.06 antihypertendsive, and fixed association of 2 or more antihypertensive drugs were used by 40.9% of the studied patients. The annual cost per patient was 141.45 €/year.

Conclusions

The study reveals strong adherence to the SEH-LELHA 2022 guidelines among physicians in Andalusia regarding the of antihypertensives for T2D patients, with a significant preference for Renin-Angiotensin System blockers, diuretics, and beta-blockers. However, a notable deviation in prescription practices was observed with the frequent choice of doxazosin over spironolactone, despite the latter being the recommended option for resistant hypertension. Although the overall expenditure on antihypertensives is moderate, their cost-effectiveness is enhanced by the efficacy of these treatments in preventing cardiovascular complications.
研究目的本研究旨在分析安达卢西亚地区 2 型糖尿病(T2D)患者的降压药处方,将其与 SEH-LELHA 2022 指南进行比较,并评估这些治疗的直接成本:对 385 名 T2D 患者进行了多中心、横断面和描述性研究。参与者从安达卢西亚 120 名初级保健医生的患者名单中随机抽取。纳入标准包括 T2D 诊断和 2022 年的完整临床记录。研究人员收集了人口统计学数据和药物处方信息,并计算了每位患者的平均费用:研究对象的平均年龄为 70.72 岁,男性占 53.51%。共有 70.9% 的患者正在服用降压药,其中最常见的是 ACE 抑制剂/ARB(70.9%)、利尿剂(70.1%)、β-受体阻滞剂(40.0%)和钙通道阻滞剂(20.0%)。每位患者平均服用 2.46±1.06 种降压药,40.9% 的研究对象使用 2 种或 2 种以上降压药的固定组合。每位患者每年的费用为 141.45 欧元/年:这项研究表明,安达卢西亚的医生在为 T2D 患者使用降压药时非常遵守 SEH-LELHA 2022 指南,并明显偏爱肾素-血管紧张素系统阻滞剂、利尿剂和β-受体阻滞剂。然而,处方做法出现了明显的偏差,经常选择多沙唑嗪而不是螺内酯,尽管后者是治疗抵抗性高血压的推荐选择。虽然抗高血压药物的总体支出不高,但这些治疗方法在预防心血管并发症方面的功效提高了其成本效益。
{"title":"Prescripción de antihipertensivos en personas con diabetes tipo 2 en Andalucía y recomendaciones SEH-LELHA 2022: evaluación del coste y uso","authors":"D. Martín-Enguix ,&nbsp;J.C. Aguirre Rodríguez ,&nbsp;M. Guisasola Cárdenas ,&nbsp;M.N. Generoso Torres ,&nbsp;A. Hidalgo Rodríguez ,&nbsp;M. Sánchez Cambronero ,&nbsp;A. González Bravo","doi":"10.1016/j.hipert.2024.06.004","DOIUrl":"10.1016/j.hipert.2024.06.004","url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to analyze the prescription of antihypertensive drugs in patients with type 2 diabetes (T2D) in Andalusia, comparing it with the SEH-LELHA 2022 guidelines, and to assess the direct cost of these treatments.</div></div><div><h3>Materials and methods</h3><div>A multicentric, cross-sectional, and descriptive study was conducted with 385 T2D patients. Participants were randomly selected from the patient lists of 120 primary care physicians from Andalusia. Inclusion criteria included a diagnosis of T2D and complete clinical records for the year 2022. Demographic data and drug prescription information were collected, with the average cost per patient being calculated.</div></div><div><h3>Results</h3><div>The mean age of the subjects was 70.72 years, with 53.51% being male. A total of 70.9% of the patients were taking antihypertensive drugs, the most common being ACE inhibitors/ARBs (70.9%), diuretics (70.1%), beta-blockers (40.0%), and calcium channel blockers (20.0%). Each patient took an average of 2.46<!--> <!-->±<!--> <!-->1.06 antihypertendsive, and fixed association of 2 or more antihypertensive drugs were used by 40.9% of the studied patients. The annual cost per patient was 141.45<!--> <!-->€/year.</div></div><div><h3>Conclusions</h3><div>The study reveals strong adherence to the SEH-LELHA 2022 guidelines among physicians in Andalusia regarding the of antihypertensives for T2D patients, with a significant preference for Renin-Angiotensin System blockers, diuretics, and beta-blockers. However, a notable deviation in prescription practices was observed with the frequent choice of doxazosin over spironolactone, despite the latter being the recommended option for resistant hypertension. Although the overall expenditure on antihypertensives is moderate, their cost-effectiveness is enhanced by the efficacy of these treatments in preventing cardiovascular complications.</div></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"41 4","pages":"Pages 226-231"},"PeriodicalIF":1.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141591630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recommendations for the management of patients with type 2 diabetes at hospital discharge after an ischaemic cardiovascular event 缺血性心血管事件后出院时对 2 型糖尿病患者的管理建议。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.hipert.2024.07.006
N.F. Renna , E.J. Zaidel , P. Corral , A.D. Lerner
The document outlines recommendations for the management of patients with type 2 diabetes (T2D) at hospital discharge following an ischaemic cardiovascular event. Diabetes significantly increases the risk of cardiovascular events, and a high proportion of patients in coronary units have this condition. The discharge process is crucial for optimising treatments and reducing the risk of recurrent complications such as reinfarction, stroke, and hospitalisations for heart failure.
Strategies include rigorous control of lipid levels, recommending potent statins combined with ezetimibe and, if necessary, other drugs such as inclisiran, evolocumab, alirocumab, or bempedoic acid. Optimal antihypertensive treatment is also suggested as secondary prevention.
For patients already on insulin, it is essential to adjust the dosage when adding SGLT-2 inhibitors (SGLT2i) or GLP-1 receptor agonists (GLP-1RA) to avoid hypoglycaemia, with structured glucose monitoring. In cases where HbA1c is not available during hospitalisation, the algorithm guides treatment, highlighting that GLP-1RA and SGLT2i do not cause hypoglycaemia. The combination of these drugs is safe and effective, improving several cardiovascular risk factors.
The document emphasises the importance of education on nutrition and healthy habits, as well as the follow-up and adjustment of pharmacological treatments to achieve adequate metabolic control and reduce cardiovascular risks. Nutritional evaluation and control are essential, considering obesity as a critical factor in T2D and its association with the risk of recurrent cardiovascular events.
该文件概述了缺血性心血管事件后出院时对 2 型糖尿病 (T2D) 患者的管理建议。糖尿病会大大增加心血管事件的风险,冠心病病房的患者中有很大一部分患有糖尿病。出院过程对于优化治疗和降低再次发生并发症(如再梗塞、中风和心力衰竭住院)的风险至关重要。治疗策略包括严格控制血脂水平,建议使用强效他汀类药物联合依折麦布,必要时还可使用其他药物,如 inclisiran、evolocumab、alirocumab 或贝美度酸。作为二级预防,还建议进行最佳降压治疗。对于已经使用胰岛素的患者,在添加 SGLT-2 抑制剂(SGLT2i)或 GLP-1 受体激动剂(GLP-1RA)时,必须调整剂量以避免出现低血糖,并进行结构化血糖监测。在住院期间无法获得 HbA1c 的情况下,该算法可指导治疗,并强调 GLP-1RA 和 SGLT2i 不会导致低血糖。这些药物的联合使用安全有效,可改善多种心血管风险因素。文件强调了营养教育和健康习惯的重要性,以及药物治疗的随访和调整,以实现充分的代谢控制和降低心血管风险。考虑到肥胖是导致终末期糖尿病的关键因素,而且与复发性心血管事件的风险有关,因此营养评估和控制至关重要。
{"title":"Recommendations for the management of patients with type 2 diabetes at hospital discharge after an ischaemic cardiovascular event","authors":"N.F. Renna ,&nbsp;E.J. Zaidel ,&nbsp;P. Corral ,&nbsp;A.D. Lerner","doi":"10.1016/j.hipert.2024.07.006","DOIUrl":"10.1016/j.hipert.2024.07.006","url":null,"abstract":"<div><div>The document outlines recommendations for the management of patients with type 2 diabetes (T2D) at hospital discharge following an ischaemic cardiovascular event. Diabetes significantly increases the risk of cardiovascular events, and a high proportion of patients in coronary units have this condition. The discharge process is crucial for optimising treatments and reducing the risk of recurrent complications such as reinfarction, stroke, and hospitalisations for heart failure.</div><div>Strategies include rigorous control of lipid levels, recommending potent statins combined with ezetimibe and, if necessary, other drugs such as inclisiran, evolocumab, alirocumab, or bempedoic acid. Optimal antihypertensive treatment is also suggested as secondary prevention.</div><div>For patients already on insulin, it is essential to adjust the dosage when adding SGLT-2 inhibitors (SGLT2i) or GLP-1 receptor agonists (GLP-1RA) to avoid hypoglycaemia, with structured glucose monitoring. In cases where HbA1c is not available during hospitalisation, the algorithm guides treatment, highlighting that GLP-1RA and SGLT2i do not cause hypoglycaemia. The combination of these drugs is safe and effective, improving several cardiovascular risk factors.</div><div>The document emphasises the importance of education on nutrition and healthy habits, as well as the follow-up and adjustment of pharmacological treatments to achieve adequate metabolic control and reduce cardiovascular risks. Nutritional evaluation and control are essential, considering obesity as a critical factor in T2D and its association with the risk of recurrent cardiovascular events.</div></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"41 4","pages":"Pages 251-259"},"PeriodicalIF":1.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Consecuencia de los trastornos hipertensivos durante el embarazo (THE) sobre la salud cardiovascular de la mujer [妊娠期高血压疾病(THE)对妇女心血管健康的影响]。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.hipert.2024.04.005
W.G. Espeche , P. Carrera Ramos , J. Minetto , D. Gomez , A. De Iraola , G.R. Cerri , M.R. Salazar
Patients with hypertensive disorders of pregnancy (HDP) are at increased risk of maternal-fetal complications and represent the third leading cause of maternal mortality. To date, it is known that women experiencing this condition during pregnancy have a higher future risk of cardiovascular events (CVD). Our objective was to report the incidence of new-onset hypertension in the postpartum period. We conducted a cohort study in high-risk pregnant patients who underwent ambulatory blood pressure monitoring (ABPM) between weeks 20-30. Patients were categorized as normotensive (NT) or gestational hypertensive (GH), excluding those with chronic hypertension, and were followed until the end of pregnancy with a postpartum assessment after 3 months. Patients with HDP (39%) had a higher incidence of preeclampsia and newborns with low birth weight and preterm birth. A total of 177 pregnant women were analyzed for the primary outcome. Among those with GH, 33.3% vs 17.2% of NT (P = .014) reported new-onset hypertension. The odds ratio for developing new-onset hypertension was 2.3 (95% CI: 1.20-4.77), for those with GH. In conclusion, pregnant patients with GH assessed by ABPM between 20-30 weeks are at higher risk of developing new-onset hypertension in the postpartum period, emphasizing the need for closer monitoring and control to prevent future cardiovascular complications.
妊娠期高血压疾病(HDP)患者发生母胎并发症的风险增加,是导致孕产妇死亡的第三大原因。迄今为止,人们已经知道,在妊娠期间患有这种疾病的妇女未来发生心血管事件(CVD)的风险较高。我们的目的是报告产后新发高血压的发病率。我们对在怀孕 20-30 周期间接受动态血压监测 (ABPM) 的高危孕妇进行了一项队列研究。患者被分为血压正常(NT)和妊娠高血压(GH)两类,其中不包括慢性高血压患者,随访至妊娠结束,并在产后 3 个月进行评估。妊娠高血压患者(39%)的子痫前期、新生儿低出生体重和早产的发生率较高。共有 177 名孕妇接受了主要结果分析。在患有 GH 的孕妇中,33.3%(P=0.014)与 17.2%(P=0.014)的 NT 孕妇报告了新发高血压。GH患者新发高血压的几率比为2.3(95%CI:1.20-4.77)。总之,在20-30周期间接受ABPM评估的GH孕妇在产后罹患新发高血压的风险较高,这强调了更密切监测和控制以预防未来心血管并发症的必要性。
{"title":"Consecuencia de los trastornos hipertensivos durante el embarazo (THE) sobre la salud cardiovascular de la mujer","authors":"W.G. Espeche ,&nbsp;P. Carrera Ramos ,&nbsp;J. Minetto ,&nbsp;D. Gomez ,&nbsp;A. De Iraola ,&nbsp;G.R. Cerri ,&nbsp;M.R. Salazar","doi":"10.1016/j.hipert.2024.04.005","DOIUrl":"10.1016/j.hipert.2024.04.005","url":null,"abstract":"<div><div>Patients with hypertensive disorders of pregnancy (HDP) are at increased risk of maternal-fetal complications and represent the third leading cause of maternal mortality. To date, it is known that women experiencing this condition during pregnancy have a higher future risk of cardiovascular events (CVD). Our objective was to report the incidence of new-onset hypertension in the postpartum period. We conducted a cohort study in high-risk pregnant patients who underwent ambulatory blood pressure monitoring (ABPM) between weeks 20-30. Patients were categorized as normotensive (NT) or gestational hypertensive (GH), excluding those with chronic hypertension, and were followed until the end of pregnancy with a postpartum assessment after 3<!--> <!-->months. Patients with HDP (39%) had a higher incidence of preeclampsia and newborns with low birth weight and preterm birth. A total of 177 pregnant women were analyzed for the primary outcome. Among those with GH, 33.3% vs 17.2% of NT (<em>P</em> <!-->=<!--> <!-->.014) reported new-onset hypertension. The odds ratio for developing new-onset hypertension was 2.3 (95%<!--> <!-->CI: 1.20-4.77), for those with GH. In conclusion, pregnant patients with GH assessed by ABPM between 20-30<!--> <!-->weeks are at higher risk of developing new-onset hypertension in the postpartum period, emphasizing the need for closer monitoring and control to prevent future cardiovascular complications.</div></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"41 4","pages":"Pages 211-216"},"PeriodicalIF":1.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140923622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Seventy years of pheochromocytomas and paragangliomas in Argentina. The FRENAR database 阿根廷嗜铬细胞瘤和副神经节瘤七十年。FRENAR 数据库。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-01 DOI: 10.1016/j.hipert.2024.04.001

Pheochromocytomas and paragangliomas (PPGL) are neuroendocrine tumors characterized by the excessive production of catecholamines. This study aims to describe the clinical characteristics of PPGL cases in Argentina over recent decades. A multicenter retrospective cross-sectional analysis was carried out using a database comprising both pediatric and adult patients with confirmed PPGL diagnoses based on pathological reports.

A cohort of 486 patients with PPGL was recruited. Women represent 58.4% of the patients, with a mean age of 38.3 years old at the time of diagnosis and 15.2% of the patients were under the age of 18. Hypertension, as well as classic signs and symptoms, were present in 80.9% of the patients. The adrenal incidentaloma, as a mode of presentation, increased in the last two decades rising from 3.9% (1953–2000) to 21.8% (2001–2022), p < 0.001.

Most tumors were located within the adrenal glands, accounting 83.0% of the cases, with bilateral occurrences noted in 20.0%. The median tumor size was 4.8 cm. Local recurrence and metastases were observed in 10.9% and 12.2%. Out of 412 patients, 87.0% exhibited urinary excretion elevation of catecholamines and/or their metabolites. Furthermore, 148 patients, representing 30.4% of the study population, displayed a distinct genetic profile indicative of hereditary syndromes. The distribution of hereditary syndromes revealed that MEN2, VHL, and PGL4 constituted the most prevalent syndromes.

This population-based study, spanning seven decades, offers valuable insights into the demographic and clinical characteristics of PPGL patients in Argentina.

嗜铬细胞瘤和副神经节瘤(PPGL)是以儿茶酚胺分泌过多为特征的神经内分泌肿瘤。本研究旨在描述近几十年来阿根廷 PPGL 病例的临床特征。研究利用一个数据库进行了多中心回顾性横断面分析,该数据库包括根据病理报告确诊为 PPGL 的儿童和成人患者。共招募了 486 名 PPGL 患者。女性患者占 58.4%,确诊时的平均年龄为 38.3 岁,15.2% 的患者未满 18 岁。80.9%的患者有高血压以及典型的体征和症状。在过去二十年中,肾上腺偶发瘤的发病率有所上升,从 3.9%(1953-2000 年)上升到 21.8%(2001-2022 年),P<0.05。
{"title":"Seventy years of pheochromocytomas and paragangliomas in Argentina. The FRENAR database","authors":"","doi":"10.1016/j.hipert.2024.04.001","DOIUrl":"10.1016/j.hipert.2024.04.001","url":null,"abstract":"<div><p>Pheochromocytomas and paragangliomas (PPGL) are neuroendocrine tumors characterized by the excessive production of catecholamines. This study aims to describe the clinical characteristics of PPGL cases in Argentina over recent decades. A multicenter retrospective cross-sectional analysis was carried out using a database comprising both pediatric and adult patients with confirmed PPGL diagnoses based on pathological reports.</p><p>A cohort of 486 patients with PPGL was recruited. Women represent 58.4% of the patients, with a mean age of 38.3 years old at the time of diagnosis and 15.2% of the patients were under the age of 18. Hypertension, as well as classic signs and symptoms, were present in 80.9% of the patients. The adrenal incidentaloma, as a mode of presentation, increased in the last two decades rising from 3.9% (1953–2000) to 21.8% (2001–2022), <em>p</em> <!-->&lt;<!--> <!-->0.001.</p><p>Most tumors were located within the adrenal glands, accounting 83.0% of the cases, with bilateral occurrences noted in 20.0%. The median tumor size was 4.8<!--> <!-->cm. Local recurrence and metastases were observed in 10.9% and 12.2%. Out of 412 patients, 87.0% exhibited urinary excretion elevation of catecholamines and/or their metabolites. Furthermore, 148 patients, representing 30.4% of the study population, displayed a distinct genetic profile indicative of hereditary syndromes. The distribution of hereditary syndromes revealed that MEN2, VHL, and PGL4 constituted the most prevalent syndromes.</p><p>This population-based study, spanning seven decades, offers valuable insights into the demographic and clinical characteristics of PPGL patients in Argentina.</p></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"41 3","pages":"Pages 170-178"},"PeriodicalIF":1.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140868345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vitamin D3 supplementation in COVID-19 patients with cardiovascular disease and gut dysbiosis 在患有心血管疾病和肠道菌群失调的 COVID-19 患者中补充维生素 D3。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-01 DOI: 10.1016/j.hipert.2024.04.002

Background

The COVID-19 pandemic has highlighted the vulnerability of particular patient groups to SARS-CoV-2 infection, including those with cardiovascular diseases, hypertension, and intestinal dysbiosis. COVID-19 affects the gut, suggesting diet and vitamin D3 supplementation may affect disease progression.

Aims

To evaluate levels of Ang II and Ang-(1–7), cytokine profile, and gut microbiota status in patients hospitalized for mild COVID-19 with a history of cardiovascular disease and treated with daily doses of vitamin D3.

Methods

We recruited 50 adult patients. We screened 50 adult patients and accessed pathophysiology study 22, randomized to daily oral doses of 10,000 IU vitamin D3 (n = 11) or placebo (n = 11). Plasma levels of Ang II and Ang-(1–7) were determined by radioimmunoassay, TMA and TMAO were measured by liquid chromatography and interleukins (ILs) 6, 8, 10 and TNF-α by ELISA.

Results

The Ang-(1–7)/Ang II ratio, as an indirect measure of ACE2 enzymatic activity, increased in the vitamin D3 group (24 ± 5 pg/mL vs. 4.66 ± 2 pg/mL, p < 0.01). Also, in the vitamin D3-treated, there was a significant decline in inflammatory ILs and an increase in protective markers, such as a substantial reduction in TMAO (5 ± 2 μmoles/dL vs. 60 ± 10 μmoles/dL, p < 0.01). In addition, treated patients experienced less severity of infection, required less intensive care, had fewer days of hospitalization, and a reduced mortality rate. Additionally, improvements in markers of cardiovascular function were seen in the vitamin D3 group, including a tendency for reductions in blood pressure in hypertensive patients.

Conclusions

Vitamin D3 supplementation in patients with COVID-19 and specific conditions is associated with a more favourable prognosis, suggesting therapeutic potential in patients with comorbidities such as cardiovascular disease and gut dysbiosis.

背景:COVID-19大流行突显了特定患者群体易受SARS-CoV-2感染,包括心血管疾病患者、高血压患者和肠道菌群失调患者。COVID-19会影响肠道,这表明饮食和维生素D3的补充可能会影响疾病的进展。目的:评估有心血管疾病史的轻度COVID-19住院患者的Ang II和Ang-(1-7)水平、细胞因子谱和肠道微生物群状况,并接受每日剂量的维生素D3治疗:我们招募了 50 名成年患者。我们筛选了 50 名成年患者,并访问了病理生理学研究 22 人,他们随机接受每日口服 10,000IU 维生素 D3(11 人)或安慰剂(11 人)。血浆中 Ang II 和 Ang-(1-7) 的水平通过放射免疫测定法进行测定,TMA 和 TMAO 通过液相色谱法进行测定,白细胞介素(ILs)6、8、10 和 TNF-α 通过酶联免疫吸附法进行测定:结果:作为 ACE2 酶活性间接测量指标的 Ang-(1-7)/Ang II 比率在维生素 D3 组有所增加(24±5pg/mL vs. 4.66±2pg/mL,p结论:COVID-19和特定病症患者补充维生素D3与更有利的预后有关,这表明维生素D3对心血管疾病和肠道菌群失调等合并症患者具有治疗潜力。
{"title":"Vitamin D3 supplementation in COVID-19 patients with cardiovascular disease and gut dysbiosis","authors":"","doi":"10.1016/j.hipert.2024.04.002","DOIUrl":"10.1016/j.hipert.2024.04.002","url":null,"abstract":"<div><h3>Background</h3><p>The COVID-19 pandemic has highlighted the vulnerability of particular patient groups to SARS-CoV-2 infection, including those with cardiovascular diseases, hypertension, and intestinal dysbiosis. COVID-19 affects the gut, suggesting diet and vitamin D3 supplementation may affect disease progression.</p></div><div><h3>Aims</h3><p>To evaluate levels of Ang II and Ang-(1–7), cytokine profile, and gut microbiota status in patients hospitalized for mild COVID-19 with a history of cardiovascular disease and treated with daily doses of vitamin D3.</p></div><div><h3>Methods</h3><p>We recruited 50 adult patients. We screened 50 adult patients and accessed pathophysiology study 22, randomized to daily oral doses of 10,000<!--> <!-->IU vitamin D3 (<em>n</em> <!-->=<!--> <!-->11) or placebo (<em>n</em> <!-->=<!--> <!-->11). Plasma levels of Ang II and Ang-(1–7) were determined by radioimmunoassay, TMA and TMAO were measured by liquid chromatography and interleukins (ILs) 6, 8, 10 and TNF-α by ELISA.</p></div><div><h3>Results</h3><p>The Ang-(1–7)/Ang II ratio, as an indirect measure of ACE2 enzymatic activity, increased in the vitamin D3 group (24<!--> <!-->±<!--> <!-->5<!--> <!-->pg/mL vs. 4.66<!--> <!-->±<!--> <!-->2<!--> <!-->pg/mL, <em>p</em> <!-->&lt;<!--> <!-->0.01). Also, in the vitamin D3-treated, there was a significant decline in inflammatory ILs and an increase in protective markers, such as a substantial reduction in TMAO (5<!--> <!-->±<!--> <!-->2<!--> <!-->μmoles/dL vs. 60<!--> <!-->±<!--> <!-->10<!--> <!-->μmoles/dL, <em>p</em> <!-->&lt;<!--> <!-->0.01). In addition, treated patients experienced less severity of infection, required less intensive care, had fewer days of hospitalization, and a reduced mortality rate. Additionally, improvements in markers of cardiovascular function were seen in the vitamin D3 group, including a tendency for reductions in blood pressure in hypertensive patients.</p></div><div><h3>Conclusions</h3><p>Vitamin D3 supplementation in patients with COVID-19 and specific conditions is associated with a more favourable prognosis, suggesting therapeutic potential in patients with comorbidities such as cardiovascular disease and gut dysbiosis.</p></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"41 3","pages":"Pages 145-153"},"PeriodicalIF":1.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141318541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diuretics use in the management of hypertension 在高血压治疗中使用利尿剂。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-01 DOI: 10.1016/j.hipert.2024.03.004

Diuretics have been used for decades in the treatment of hypertension. Its efficacy has been demonstrated in numerous clinical trials. It is well known that the reduction in cardiovascular risk is a consequence of the reduction in blood pressure levels regardless of the drug used, but thiazide diuretics continue to be first-line drugs, especially in low doses and combined with other drugs. The debate on the advantages of using chlorthalidone or hydrochlorothiazide continues, however hydrochlorothiazide is drug most used and for which there is greater availability. The association with potassium-sparing diuretics increases the effectiveness and reduces the adverse reactions of thiazides. A new group of drugs, close to potassium-sparing diuretics, that antagonise aldosterone synthase are showing promising results as antihypertensives. There are no significant differences between men and women regarding the antihypertensive effect of thiazide diuretics.

几十年来,利尿剂一直被用于治疗高血压。许多临床试验都证明了其疗效。众所周知,无论使用哪种药物,心血管风险的降低都是血压水平降低的结果,但噻嗪类利尿剂仍是一线药物,尤其是小剂量和与其他药物联合使用时。关于使用氯塞酮或氢氯噻嗪的优势的争论仍在继续,但氢氯噻嗪是使用最多的药物,也更容易获得。与保钾利尿剂合用可提高噻嗪类药物的疗效,并减少其不良反应。与保钾利尿剂相近的一类新药是拮抗醛固酮合成酶的药物,作为降压药使用效果很好。在噻嗪类利尿剂的降压效果方面,男女之间没有明显差异。
{"title":"Diuretics use in the management of hypertension","authors":"","doi":"10.1016/j.hipert.2024.03.004","DOIUrl":"10.1016/j.hipert.2024.03.004","url":null,"abstract":"<div><p>Diuretics have been used for decades in the treatment of hypertension. Its efficacy has been demonstrated in numerous clinical trials. It is well known that the reduction in cardiovascular risk is a consequence of the reduction in blood pressure levels regardless of the drug used, but thiazide diuretics continue to be first-line drugs, especially in low doses and combined with other drugs. The debate on the advantages of using chlorthalidone or hydrochlorothiazide continues, however hydrochlorothiazide is drug most used and for which there is greater availability. The association with potassium-sparing diuretics increases the effectiveness and reduces the adverse reactions of thiazides. A new group of drugs, close to potassium-sparing diuretics, that antagonise aldosterone synthase are showing promising results as antihypertensives. There are no significant differences between men and women regarding the antihypertensive effect of thiazide diuretics.</p></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"41 3","pages":"Pages 186-193"},"PeriodicalIF":1.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1889183724000540/pdfft?md5=570c19be134f3cfcb158437971852d9e&pid=1-s2.0-S1889183724000540-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141296937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can catheter-based renal denervation reduce frequency of hospitalization in patients who have resistant hypertension and heart failure with reduced ejection fraction? 基于导管的肾脏去神经化能否减少抵抗性高血压和射血分数降低型心力衰竭患者的住院次数?
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-01 DOI: 10.1016/j.hipert.2024.03.003

Hypertension is one of the most powerful and modifiable risk factors for the development, progression and even decompensation of heart failure. Uncontrolled hypertension increases to frequency of heart failure hospitalizations by increase sympathetic tone. Catheter-based renal denervation has been shown to reduce blood pressure in the treatment of multidrug-resistant hypertension. We report the improvement in clinical status after renal denervation in a 47-year-old male patient with a history of hypertension, chronic ischemic heart failure, and recurrent hospitalizations for acute hypertensive pulmonary edema despite optimal medical therapy.

高血压是导致心力衰竭发生、发展甚至失代偿的最主要、最可改变的危险因素之一。不受控制的高血压会增加交感神经张力,从而增加心力衰竭住院的频率。在治疗耐多药高血压的过程中,导管肾去神经被证明可以降低血压。我们报告了一名 47 岁男性患者在接受肾脏神经支配治疗后临床状况的改善情况,该患者有高血压、慢性缺血性心力衰竭病史,尽管接受了最佳的药物治疗,但仍因急性高血压肺水肿反复住院。
{"title":"Can catheter-based renal denervation reduce frequency of hospitalization in patients who have resistant hypertension and heart failure with reduced ejection fraction?","authors":"","doi":"10.1016/j.hipert.2024.03.003","DOIUrl":"10.1016/j.hipert.2024.03.003","url":null,"abstract":"<div><p>Hypertension is one of the most powerful and modifiable risk factors for the development, progression and even decompensation of heart failure. Uncontrolled hypertension increases to frequency of heart failure hospitalizations by increase sympathetic tone. Catheter-based renal denervation has been shown to reduce blood pressure in the treatment of multidrug-resistant hypertension. We report the improvement in clinical status after renal denervation in a 47-year-old male patient with a history of hypertension, chronic ischemic heart failure, and recurrent hospitalizations for acute hypertensive pulmonary edema despite optimal medical therapy.</p></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"41 3","pages":"Pages 198-200"},"PeriodicalIF":1.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140762460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Miocardiopatía periparto con fallo biventricular más tromboembolismo pulmonar y comunicación interauricular [伴有双心室衰竭、肺血栓栓塞症和房间隔缺损的围产期心肌病]。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-01 DOI: 10.1016/j.hipert.2024.03.002

This case report examines peripartum cardiomyopathy (PPCM), a rare variant of heart failure with reduced ejection fraction, which manifests at the end of labor or puerperium. The frequency of this pathology varies globally, and its association with risk factors such as genetic disorders, autoimmune diseases, viral infections, suggests a multifactorial etiology. Diagnostic criteria include: Heart failure secondary to left ventricular systolic dysfunction, manifested in the puerperium or at the end of pregnancy and lack of other identifiable causes of heart failure. The case presents a patient with no significant personal pathological history, who, 17 days post cesarean section developed acute symptoms, including abdominal pain, dry cough and dyspnea. Clinical findings revealed hypoxemia, alterations in blood tests and an echocardiogram that confirmed an atrial septal defect. Multidisciplinary management resulted in successful treatment and the patient was discharged without complications.

This case highlights the importance of MCPP, a disease with high maternal mortality. The connection between atrial septal defect and PPCM, as well as the involvement of pulmonary thromboembolism.

本病例报告探讨了围产期心肌病(PPCM),这是一种罕见的射血分数降低型心力衰竭,表现为临产或产褥期心力衰竭。这种病症在全球的发病率不尽相同,而且与遗传疾病、自身免疫性疾病、病毒感染等危险因素有关,这表明其病因是多因素的。诊断标准包括继发于左心室收缩功能障碍的心力衰竭,表现在产褥期或妊娠末期,且缺乏其他可确定的心力衰竭原因。本病例中的患者无明显个人病史,在剖宫产术后 17 天出现急性症状,包括腹痛、干咳和呼吸困难。临床表现为低氧血症、血液化验结果改变,超声心动图证实为房间隔缺损。该病例凸显了产妇死亡率较高的一种疾病--MCPP 的重要性。本病例强调了 MCPP 这种产妇死亡率很高的疾病的重要性,以及房间隔缺损与 PPCM 之间的联系和肺血栓栓塞症的参与。
{"title":"Miocardiopatía periparto con fallo biventricular más tromboembolismo pulmonar y comunicación interauricular","authors":"","doi":"10.1016/j.hipert.2024.03.002","DOIUrl":"10.1016/j.hipert.2024.03.002","url":null,"abstract":"<div><p>This case report examines peripartum cardiomyopathy (PPCM), a rare variant of heart failure with reduced ejection fraction, which manifests at the end of labor or puerperium. The frequency of this pathology varies globally, and its association with risk factors such as genetic disorders, autoimmune diseases, viral infections, suggests a multifactorial etiology. Diagnostic criteria include: Heart failure secondary to left ventricular systolic dysfunction, manifested in the puerperium or at the end of pregnancy and lack of other identifiable causes of heart failure. The case presents a patient with no significant personal pathological history, who, 17 days post cesarean section developed acute symptoms, including abdominal pain, dry cough and dyspnea. Clinical findings revealed hypoxemia, alterations in blood tests and an echocardiogram that confirmed an atrial septal defect. Multidisciplinary management resulted in successful treatment and the patient was discharged without complications.</p><p>This case highlights the importance of MCPP, a disease with high maternal mortality. The connection between atrial septal defect and PPCM, as well as the involvement of pulmonary thromboembolism.</p></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"41 3","pages":"Pages 194-197"},"PeriodicalIF":1.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140777537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Valor de la fórmula hematocrito urea y género basal en la evolución a los 17 años de la función renal de ancianos [血细胞比容尿素和性别公式基线对 17 岁老年人肾功能演变的价值]。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-01 DOI: 10.1016/j.hipert.2024.03.001
{"title":"Valor de la fórmula hematocrito urea y género basal en la evolución a los 17 años de la función renal de ancianos","authors":"","doi":"10.1016/j.hipert.2024.03.001","DOIUrl":"10.1016/j.hipert.2024.03.001","url":null,"abstract":"","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"41 3","pages":"Pages 201-202"},"PeriodicalIF":1.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140782830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing levels of uric acid and other cardiovascular markers in prehypertensive and hypertensive adults 评估高血压前期和高血压成人的尿酸水平及其他心血管指标。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-01 DOI: 10.1016/j.hipert.2024.04.003

Introduction

Although some studies have reported the association between uric acid (UA) and hypertension, evidence on prehypertension is still lacking. Therefore, the objective of this study was to determine the levels of UA and other cardiovascular markers among prehypertensive and hypertensive patients and assess their risk for developing arterial hypertension.

Methods

157 individuals were recruited: 67 normotensive, 23 pre-hypertensive and 67 hypertensive. Blood samples were collected to measure biochemical parameters and anthropometric measurements and blood pressure were evaluated. We calculated the product of lipid accumulation and the visceral adiposity index to assess cardiovascular risk.

Results

Our data showed an increase in UA levels in normotensives (4.9 ± 1.3 mg/dL), prehypertensives (5.2 ± 1.3 mg/dL) and hypertensives (5.9 ± 1.6 mg/dL) (p = 0.004). We found a higher frequency of hyperuricemia in the hypertensive group (34.3%) than in the normotensive group (13.4%, p < 0.05). Hypertensive volunteers had lower levels of HDL-C (p = 0.004 and p = 0.003) and higher body mass indexes (p < 0.001 and p = 0.007), glucose (p < 0.001 and p = 0.033), triglycerides (p = 0.001 and p = 0.005), visceral adiposity index (p < 0.001 and p = 0.002) and lipid accumulation product (p < 0.001 and p = 0.007) than normotensive and prehypertensive participants. We also observed that individuals with UA  6.2 mg/dL had an increased risk of hypertension of 4.77 (p = 0.003) compared to individuals with levels  4.3 mg/dL.

Conclusion

Our results showed that UA is associated with increased blood pressure and unfavorable changes in anthropometric and biochemical parameters, which represent risk factors for hypertension and cardiovascular diseases.

导言:尽管一些研究报告了尿酸(UA)与高血压之间的关系,但仍缺乏有关高血压前期的证据。因此,本研究旨在确定高血压前期和高血压患者的尿酸水平及其他心血管标志物,并评估他们患动脉高血压的风险:方法:招募了 157 人:67 名血压正常者、23 名高血压前期患者和 67 名高血压患者。收集血液样本以测量生化参数,并对人体测量数据和血压进行评估。我们计算了脂质积累与内脏脂肪指数的乘积,以评估心血管风险:我们的数据显示,血压正常者(4.9±1.3mg/dL)、高血压前期者(5.2±1.3mg/dL)和高血压患者(5.9±1.6mg/dL)的尿酸水平均有所上升(P=0.004)。我们发现高血压组(34.3%)出现高尿酸血症的频率高于正常血压组(13.4%,P=0.004):我们的研究结果表明,尿酸与血压升高以及人体测量和生化指标的不利变化有关,这些都是高血压和心血管疾病的危险因素。
{"title":"Assessing levels of uric acid and other cardiovascular markers in prehypertensive and hypertensive adults","authors":"","doi":"10.1016/j.hipert.2024.04.003","DOIUrl":"10.1016/j.hipert.2024.04.003","url":null,"abstract":"<div><h3>Introduction</h3><p>Although some studies have reported the association between uric acid (UA) and hypertension, evidence on prehypertension is still lacking. Therefore, the objective of this study was to determine the levels of UA and other cardiovascular markers among prehypertensive and hypertensive patients and assess their risk for developing arterial hypertension.</p></div><div><h3>Methods</h3><p>157 individuals were recruited: 67 normotensive, 23 pre-hypertensive and 67 hypertensive. Blood samples were collected to measure biochemical parameters and anthropometric measurements and blood pressure were evaluated. We calculated the product of lipid accumulation and the visceral adiposity index to assess cardiovascular risk.</p></div><div><h3>Results</h3><p>Our data showed an increase in UA levels in normotensives (4.9<!--> <!-->±<!--> <!-->1.3<!--> <!-->mg/dL), prehypertensives (5.2<!--> <!-->±<!--> <!-->1.3<!--> <!-->mg/dL) and hypertensives (5.9<!--> <!-->±<!--> <!-->1.6<!--> <!-->mg/dL) (<em>p</em> <!-->=<!--> <!-->0.004). We found a higher frequency of hyperuricemia in the hypertensive group (34.3%) than in the normotensive group (13.4%, <em>p</em> <!-->&lt;<!--> <!-->0.05). Hypertensive volunteers had lower levels of HDL-C (<em>p</em> <!-->=<!--> <!-->0.004 and <em>p</em> <!-->=<!--> <!-->0.003) and higher body mass indexes (<em>p</em> <!-->&lt;<!--> <!-->0.001 and <em>p</em> <!-->=<!--> <!-->0.007), glucose (<em>p</em> <!-->&lt;<!--> <!-->0.001 and <em>p</em> <!-->=<!--> <!-->0.033), triglycerides (<em>p</em> <!-->=<!--> <!-->0.001 and <em>p</em> <!-->=<!--> <!-->0.005), visceral adiposity index (<em>p</em> <!-->&lt;<!--> <!-->0.001 and <em>p</em> <!-->=<!--> <!-->0.002) and lipid accumulation product (<em>p</em> <!-->&lt;<!--> <!-->0.001 and <em>p</em> <!-->=<!--> <!-->0.007) than normotensive and prehypertensive participants. We also observed that individuals with UA<!--> <!-->≥<!--> <!-->6.2<!--> <!-->mg/dL had an increased risk of hypertension of 4.77 (<em>p</em> <!-->=<!--> <!-->0.003) compared to individuals with levels<!--> <!-->≤<!--> <!-->4.3<!--> <!-->mg/dL.</p></div><div><h3>Conclusion</h3><p>Our results showed that UA is associated with increased blood pressure and unfavorable changes in anthropometric and biochemical parameters, which represent risk factors for hypertension and cardiovascular diseases.</p></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"41 3","pages":"Pages 154-161"},"PeriodicalIF":1.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140856151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Hipertension y Riesgo Vascular
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1